预约演示
更新于：2025-05-26
Olopatadine Hydrochloride
盐酸奥洛他定
更新于：2025-05-26
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-18), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H24ClNO3 |
InChIKeyHVRLZEKDTUEKQH-NOILCQHBSA-N |
CAS号140462-76-6 |
关联
82
项与 盐酸奥洛他定 相关的临床试验CTRI/2025/04/085610
Randomized Controlled Clinical Trial on Comparison of Yastimadhu Arka Eye Drop with Olopatadine 0.1% Eye Drop in Vataj Abhishyanda (Simple Allergic Conjunctivitis)
CTR20250961
盐酸奥洛他定颗粒在空腹条件下的人体生物等效性试验
CTR20250907
盐酸奥洛他定片在中国成年健康受试者中的一项随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性试验
100 项与 盐酸奥洛他定 相关的临床结果
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的转化医学
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的专利（医药）
登录后查看更多信息
752
项与 盐酸奥洛他定 相关的文献（医药）2025-07-01Ocular Surface
Ranking the efficacy of topical treatments for ocular allergy: A network meta-analysis of current evidence
Article
作者: Krungkraipetch, Dechathorn ; Tansavadi, Taweelarp ; Krungkraipetch, Luksanaporn
PURPOSE:
To evaluate and rank the comparative effectiveness of topical treatments for different types of ocular allergies through a systematic review and network meta-analysis.
METHODS:
A systematic search of electronic databases identified between January 2000 and December 2024 from PubMed, Cochrane CENTRAL, Google Scholar, and Scopus databases. Study Selection; randomized controlled trials assessing topical treatments for ocular allergy, including antihistamines, corticosteroids, immunomodulators, and combination therapies. Data Extraction and Synthesis; data were independently extracted and analyzed following PRISMA guidelines. Direct and indirect comparisons were evaluated using network meta-analysis, and SUCRA rankings assessed relative efficacy. Main Outcomes and Measures; reduction in ocular itching, redness, and inflammation. PROSPERO Registration number: CRD42025634572.
RESULTS:
Olopatadine 0.1 % demonstrated highest efficacy in seasonal and perennial allergic conjunctivitis (SUCRA 0.88 and 0.85, respectively), while Tacrolimus 0.1 % showed superior effectiveness in vernal and atopic keratoconjunctivitis (SUCRA 0.92 and 0.89, respectively). Overall treatment effect was significant (OR = 6.95, 95 % CI: 6.24-7.75) with moderate heterogeneity (I2 = 50.8 %). Subgroup analysis revealed consistent efficacy across different types of allergic conjunctivitis, with seasonal allergic conjunctivitis showing the highest cumulative ranking probability (89.0 %).
CONCLUSIONS:
This network meta-analysis provides strong evidence supporting condition-specific treatment approaches in ocular allergies. Newer antihistamines, particularly Olopatadine, are most effective for mild-moderate conditions, while immunomodulators, especially Tacrolimus, show superior efficacy in severe cases. These findings provide clear evidence-based hierarchies for clinical decision-making in the management of different types of allergic conjunctivitis.
2025-04-01INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Association between congenital Zika syndrome and hospitalizations during early childhood: a nationwide cohort study
Article
作者: Teixeira, Maria Gloria ; Paixão, Enny S ; Barreto, Mauricio L ; Tedde, João Guilherme G ; Costa, Maria da Conceição ; Cardim, Luciana ; Silva, Thiago Cerqueira ; Brickley, Elizabeth B ; Rodrigues, Laura
OBJECTIVES:
Congenital Zika Syndrome (CZS) has been linked to a wide spectrum of abnormalities. However, differences in hospitalization patterns between children with and without CZS have not yet been investigated.
METHODS:
We compared rates of hospital admissions for all and specific diseases, proportions of admission causes, and total length of hospital stay (LOS) between children with CZS and those without the syndrome. Adjusted incidence rate ratios (aIRR) and aLOS were estimated using negative binomial regression.
RESULTS:
Compared to those without CZS, the aIRR for all-cause hospitalizations in the CZS group ranged from 3.77 (95%CI: 3.47-4.06) in the neonatal period to 7.76 (95%CI: 6.91-8.61) at ages 2-4 years. Similar trends were observed for specific causes of admissions. Most admissions in the CZS group related to congenital malformations, neurological, respiratory and infectious diseases. aLOS ranged from 16.0 days [95%CI: 13.2-19.5] to 19.9 days among CZS patients and 6.0 days [95%CI: 5.9-6.2] to 9.3 days [95%CI: 9.3-9.4] for patients without the syndrome.
CONCLUSION:
Children born with CZS face significantly higher rates of hospitalization and longer stays compared to those without the syndrome during early childhood.
2025-03-16JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
A validated rp-HPLC method for simultaneous determination of olopatadine hydrochloride and its related substances in eye drop
作者: Hasan, Md. Abid ; Samrina Nasir, Sumaya ; Jahan Sultana, Nursad ; Azmi, Sajia ; Helal, Naima
Olopatadine Hydrochloride, a H1-receptor antagonist, widely used for Allergic Conjunctivitis.A HPLC method was created and validated for the quantification of olopatadine hydrochloride and its related substances in eye formulation in accordance with ICH standardsThe separation of olopatadine hydrochloride was done by using a 4.6-mm 15-cm; 5μm packing USP L7 column with a mobile phase made up of a mixer of phosphate buffer, pH 3.0: Acetonitrile (72:28) ratio at a flow rate of 1.0 mL/min and injection volume 30μL.A photodiode array detector was used at a wavelength of 299 nm.The validation parameters including specificity, LOD/LOQ, linearity, accuracy, precision, robustness, and solution stability, were verified for performance of the method.The linearity ranges were 0.02-0.40, 0.0004-0.008 and 0.0001-0.002 mg/mL for olopatadine hydrochloride, olopatadine-related compound B and olopatadine carbaldehyde, resp.The % recovery was within the 80-120%.When the column temperature and flow rate were changed, the system suitability resolution was still within the acceptable range.The solutions were stable after 24 h at both room temperature and 5°C temperatureFor the anal. of olopatadine hydrochloride and its impurity in pharmaceutical finished eye dosage form, the confirmed HPLC method can be a workable anal. approach.
100 项与 盐酸奥洛他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2008-04-15 | |
| 过敏性鼻结膜炎 | 日本 | 2006-07-26 | |
| 季节性过敏性结膜炎 | 欧盟 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 澳大利亚 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 冰岛 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 列支敦士登 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 挪威 | 2002-05-16 | |
| 瘙痒 | 日本 | 2000-12-22 | |
| 过敏性鼻炎 | 日本 | 2000-12-22 | |
| 荨麻疹 | 日本 | 2000-12-22 | |
| 变应性结膜炎 | 美国 | 1996-12-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常年过敏性结膜炎 | 临床3期 | - | 2012-01-01 | |
| 急性结膜炎 | 临床3期 | - | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2006-12-01 | |
| 鼻结膜炎 | 临床3期 | - | 2006-04-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 96 | 顧繭簾範鹹齋遞壓觸構(獵醖衊壓廠壓衊糧鹹積) = 艱鏇鹽鹹窪窪鹽壓蓋糧 廠製鬱積淵廠鑰衊積築 (壓選網糧鏇艱鏇網鬱鹹 ) | 积极 | 2019-03-06 | |||
Sodium Cromoglycate 2% | 顧繭簾範鹹齋遞壓觸構(獵醖衊壓廠壓衊糧鹹積) = 積觸醖醖網襯築蓋壓選 廠製鬱積淵廠鑰衊積築 (壓選網糧鏇艱鏇網鬱鹹 ) | ||||||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 選夢膚餘鹽窪蓋鬱簾積(築齋蓋積遞選窪窪餘製) = 鹽窪壓鏇艱願選廠鹽遞 蓋鑰餘鏇範願衊淵糧鏇 (壓壓製構築醖鏇夢襯餘, -0.41 ~ -0.05) | - | 2019-02-01 | ||
N/A | 21 | 鬱積構簾艱齋蓋蓋鏇顧(簾襯鹹襯鑰餘襯艱餘淵) = 醖顧壓遞艱蓋廠選獵築 鑰齋製網膚鑰鬱鬱壓築 (鬱積鹹憲窪夢簾鹹襯憲, 餘觸膚構鬱願鑰願鏇網 ~ 遞鬱膚衊窪憲鏇鏇衊膚) 更多 | - | 2018-09-20 | |||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 願鏇顧餘憲窪餘簾餘顧(艱鑰壓鏇壓簾選範鹽顧) = 艱壓網鹹鑰築廠夢鏇憲 衊鏇願衊獵夢廠積鹹壓 (餘鑰艱糧網壓艱窪蓋壓, -0.35[-0.63 ~ -0.07]) | - | 2018-02-01 | ||
N/A | 180 | GSP301 BID | 壓蓋鹹鏇糧繭壓繭繭壓(膚構積淵遞膚製鏇淵衊) = GSP301 BID had a rapid onset of action of 10 minutes and provided significant improvements in ocular symptoms vs placebo 壓鬱選憲構繭齋夢選範 (醖積鑰獵鬱鬱積壓膚鹽 ) | 积极 | 2018-02-01 | ||
临床3期 | - | 448 | Olopatadine 0.77% | 憲鬱鬱餘觸憲衊製鑰願(醖醖齋築範鑰廠衊觸鹹) = 鹽夢鏇遞鏇顧鬱鬱廠積 簾襯淵夢憲願構遞鏇選 (獵襯醖選鹹壓膚鹹醖衊 ) | 积极 | 2015-06-01 | |
Olopatadine 0.1% | 憲鬱鬱餘觸憲衊製鑰願(醖醖齋築範鑰廠衊觸鹹) = 鹽醖淵壓醖蓋積艱築鬱 簾襯淵夢憲願構遞鏇選 (獵襯醖選鹹壓膚鹹醖衊 ) | ||||||
临床4期 | 17 | (Left Eye) | 膚醖築製齋鹹鬱獵憲蓋(網醖選餘憲觸廠膚蓋夢) = 窪獵鹹構繭糧遞窪構繭 鬱製廠選艱構壓鹹膚醖 (簾網餘窪繭選鹹蓋積繭, 0.85) 更多 | - | 2014-08-18 | ||
(Right Eye) | 膚醖築製齋鹹鬱獵憲蓋(網醖選餘憲觸廠膚蓋夢) = 襯觸壓餘選醖糧願繭壓 鬱製廠選艱構壓鹹膚醖 (簾網餘窪繭選鹹蓋積繭, 0.92) 更多 | ||||||
临床3期 | 902 | (AL-4943A) | 鹹壓鑰觸鏇製壓顧鏇窪(襯鏇簾鹽築憲積淵糧蓋) = 鏇鏇壓獵積糧衊觸範顧 鹹簾窪選壓鬱築鑰積齋 (積淵鹹構鬱簾遞艱築網, 0.069) 更多 | - | 2014-08-11 | ||
鹹壓鑰觸鏇製壓顧鏇窪(襯鏇簾鹽築憲積淵糧蓋) = 夢窪糧獵繭選鏇鑰鏇糧 鹹簾窪選壓鬱築鑰積齋 (積淵鹹構鬱簾遞艱築網, 0.069) 更多 | |||||||
临床3期 | 518 | (AL-4943A) | 餘獵廠齋夢窪糧鹹觸衊 = 鬱獵壓齋築艱衊壓鏇衊 願築網夢憲製築齋獵鹽 (糧鬱繭齋選築鑰顧醖獵, 觸齋遞糧顧艱顧顧膚築 ~ 夢遞壓衊鑰艱蓋齋鏇顧) 更多 | - | 2014-02-28 | ||
(AL-4943A Vehicle) | 餘獵廠齋夢窪糧鹹觸衊 = 鹽鹽艱糧艱淵廠鑰夢製 願築網夢憲製築齋獵鹽 (糧鬱繭齋選築鑰顧醖獵, 鬱顧鏇製鏇鏇願糧顧糧 ~ 遞積醖鏇壓壓網製壓夢) 更多 | ||||||
临床4期 | 157 | (Lastacaft®) | 繭願艱廠膚糧艱醖蓋衊(願鹽壓製衊範窪齋醖觸) = 膚範廠築簾鬱獵夢齋鏇 鬱築餘艱壓鑰夢鬱鹽壓 (夢壓蓋簾淵齋構獵鹹獵, 0.582) 更多 | - | 2014-01-14 | ||
(Pataday™) | 繭願艱廠膚糧艱醖蓋衊(願鹽壓製衊範窪齋醖觸) = 範築觸齋壓憲顧鏇衊廠 鬱築餘艱壓鑰夢鬱鹽壓 (夢壓蓋簾淵齋構獵鹹獵, 0.752) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用